Sugi Predict

Sugi Predict / Compounds / SCHEMBL3090186

SCHEMBL3090186

SCHEMBL3090186

CCCCCCC(=O)OC(C)OC(=O)NC1(C(=O)O)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.49
▸ MAPK1 P28482 5/20 0.43
▸ MAPT P10636 5/20 0.43
▸ ALDH1A1 P00352 1/20 0.41
▸ GMNN O75496 3/20 0.39
▸ NPSR1 Q6W5P4 3/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ HSP90AA1 P07900 2/20 0.39
▸ BLM P54132 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ NR1H4 Q96RI1 2/20 0.39
▸ SPHK1 Q9NYA1 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ PRKCA P17252 1/20 0.39
▸ PRKCE Q02156 1/20 0.39
▸ PRKCQ Q04759 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3106497 0.95 LMNA (0.41) LMNAMAPK1MAPTALDH1A1GMNN
SCHEMBL3106232 0.79 FAAH (0.46) LMNA
SCHEMBL3090188 0.78 DGKA (0.58) LMNAMAPTALDH1A1SPHK1TSHR
SCHEMBL11614143 0.78 LMNA (0.77) LMNAMAPK1MAPTALDH1A1GMNN
SCHEMBL3834695 0.78 LMNA (0.77) LMNAMAPK1MAPTALDH1A1GMNN
SCHEMBL27593159 0.78 LMNA (0.77) LMNAMAPK1MAPTALDH1A1GMNN
SCHEMBL27611224 0.78 LMNA (0.77) LMNAMAPK1MAPTALDH1A1GMNN
SCHEMBL3835899 0.78 LMNA (0.77) LMNAMAPK1MAPTALDH1A1GMNN
Acetic Acid SCHEMBL10783410 0.76 LMNA (0.69) LMNAMAPK1MAPTALDH1A1GMNN
Acetic Acid SCHEMBL8011829 0.76 LMNA (0.69) LMNAMAPK1MAPTALDH1A1GMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7531572-B2 Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use XENOPORT, INC. (US) 2009-05-12 — — US claimed
US-20080051458-A1 Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use XENOPORT, INC. 2008-02-28 — — US claimed
WO-2008013860-A2 ACYLOXYALKYL CARBAMATE PRODRUGS OF ALPHA-AMINO ACIDS, METHODS OF SYNTHESIS AND USE XENOPORT, INC. (US) 2008-01-31 — — WO claimed
US-7799829-B2 Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use XENOPORT, INC. (US) 2010-09-21 — — US disclosed
US-20090192225-A1 Acyloxyalkyl Carbamate Prodrugs of Alpha-Amino Acids, Methods of Synthesis and Use XENOPORT, INC. (US) 2009-07-30 — — US disclosed
US-7531572-B2 Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use XENOPORT, INC. (US) 2009-05-12 — — US disclosed
US-20080051458-A1 Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use XENOPORT, INC. 2008-02-28 — — US disclosed
WO-2008013860-A2 ACYLOXYALKYL CARBAMATE PRODRUGS OF ALPHA-AMINO ACIDS, METHODS OF SYNTHESIS AND USE XENOPORT, INC. (US) 2008-01-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192225-A1 Acyloxyalkyl Carbamate Prodrugs of Alpha-Amino Acids, Methods of Synthesis and Use ASNS, ASPH, DNPEP LMNA 2068/4885MAPK1 4634/4885MAPT 2188/4885
US-20080051458-A1 Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use ASNS, ASPH, DNPEP LMNA 2068/4885MAPK1 4634/4885MAPT 2188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.